Pediatric PsoriasisNCT07451626
Clinical, Epidemiologic, and Therapeutic Characterization of Pediatric Psoriasis in the Costa Rican Social Security System
An observational study of Pediatric Psoriasis, run by Caja Costarricense de Seguro Social at 1 site in Costa Rica.
Trial summary
The goal of this retrospective observational study is to characterize the clinical features, severity, comorbidities, and treatment patterns of pediatric psoriasis in patients managed in the Costa Rican Social Security System. Read more about this study
- Who is it for?
- Ages Up to 18 years
- Conditions the study is for
- Pediatric Psoriasis
- How many people
- 300 participants
- Where
- 1 siteCosta Rica
- Study dates
- May 2026to May 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: The study population comprises children and adolescents (<18 years) with confirmed psoriasis managed in the Costa Rican Social Security System in Costa Rica. This retrospective hospital-based cohort includes patients across pediatric age groups and psoriasis subtypes receiving routine dermatologic care. Data derived from electronic health records and reflect real-world pediatric psoriasis severity, comorbidities, and treatment patterns in specialized tertiary care without protocol-mandated interventions.
Who may be able to join
- Patients younger than 18 years at the time of psoriasis diagnosis.
- Clinical diagnosis of psoriasis established by a specialist physician (dermatologist or trained pediatrician) or by a general practitioner within the Costa Rican Social Security System (CCSS).
- Patients evaluated in CCSS healthcare facilities between January 2018 and December 2025.
- Clinical records containing sufficient information on key epidemiologic and therapeutic variables relevant to the study (age, sex, date of diagnosis, clinical subtype, and treatment received).
Who cannot join
- Patients aged 18 years or older at the time of psoriasis diagnosis.
- Clinical records incomplete or lacking sufficient information for analysis of the main study variables.
- Patients with uncertain or unconfirmed diagnosis of psoriasis.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Costa Rica1 site
Caja Costarricense del Seguro Social
San José, Provincia de San José, 40901
Daniel E Barquero-Orias, Dermatologist, +506 83411026, debarque@ccss.sa.cr
Daniel E Barquero-Orias, Dermatologist
About this study
Official title: Epidemiological and Therapeutic Characterization Study of Psoriatic Disease in Patients Under 18 Years of Age at the Costa Rican Social Security (2018-2025)
The goal of this retrospective observational study is to characterize the clinical features, severity, comorbidities, and treatment patterns of pediatric psoriasis in patients managed in the Costa Rican Social Security System. The main questions it aims to answer are:
What are the demographic and clinical characteristics of pediatric psoriasis in Costa Rica?
What disease severity profiles, comorbidities, and treatments are observed in routine care?
All patients <18 years with confirmed psoriasis evaluated during the study period will be included. Data will be obtained from electronic health records without intervention or modification of treatment.
Read the detailed description
Pediatric psoriasis is a chronic immune-mediated inflammatory dermatosis associated with physical, psychosocial, and metabolic comorbidity burden beginning early in life. Epidemiologic and clinical data in Latin American pediatric populations remain limited, particularly in real-world care settings. This study is a retrospective observational characterization of pediatric psoriasis patients managed in the Costa Rican Social Security System. Unlike interventional trials or biologic-specific registries, it analyzes existing clinical records to describe demographic distribution, clinical subtypes, severity (PASI/BSA/DLQI or pediatric indices), comorbidities, and treatment patterns in routine practice. No therapeutic interventions or standardized follow-up are introduced. By capturing real-world pediatric psoriasis presentation and management in Costa Rica, the study provides baseline national evidence distinct from drug-specific or prospective therapeutic studies.
- Conditions
- Pediatric Psoriasis
- Keywords
- Costa Rica, Epidemiology, Pediatric, Psoriasis, Real-Word
- Medical subject headings
- Psoriasis
What is being measured
The primary outcome is the main question the study is designed to answer.
Treatment patterns used in pediatric psoriasis in real-world clinical practice (topical, phototherapy, systemic, biologic).
Measured: January 2018- December 2025
Clinical and severity characteristics of pediatric psoriasis, including subtype and severity indices (e.g., PASI/BSA/DLQI or pediatric-adapted measures) documented in routine care.
Measured: January 2018- December 2025
Comorbidity profile in pediatric psoriasis (e.g., metabolic, cardiovascular risk factors, psoriatic arthritis).
Measured: January 2018- December 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2026
- Study startMay 2026 (estimated)
- Primary completionMay 2027 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pediatric PsoriasisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Caja Costarricense de Seguro Social
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Daniel Barquero Orias, Caja Costarricense de Seguro Social
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07451626
- Sponsor's protocol ID
- CEC HCG 15-2026
- Status last verified
- Apr 2026
- First submitted
- 28 Feb 2026
- Last updated
- 7 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: According to the protocol
Study at a glance
From the registry record, last updated by the sponsor on 7 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Epidemiological and Therapeutic Characterization Study of Psoriatic Disease in Patients Under 18 Years of Age at the Costa Rican Social Security (2018-2025)
- ClinicalTrials.gov ID
- NCT07451626
- Acronym / sponsor ID
- CEC HCG 15-2026
- Conditions
- Pediatric Psoriasis
- Keywords
- Costa Rica, Epidemiology, Pediatric, Psoriasis, Real-Word
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Caja Costarricense de Seguro SocialOther government
- Study start
- May 2026 (estimated)
- Primary completion
- May 2027 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 5 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this retrospective observational study is to characterize the clinical features, severity, comorbidities, and treatment patterns of pediatric psoriasis in patients managed in the Costa Rican Social Security System. The main questions it aims to answer are:
What are the demographic and clinical characteristics of pediatric psoriasis in Costa Rica?
What disease severity profiles, comorbidities, and treatments are observed in routine care?
All patients <18 years with confirmed psoriasis evaluated during the study period will be included. Data will be obtained from electronic health records without intervention or modification of treatment.
Detailed description
Pediatric psoriasis is a chronic immune-mediated inflammatory dermatosis associated with physical, psychosocial, and metabolic comorbidity burden beginning early in life. Epidemiologic and clinical data in Latin American pediatric populations remain limited, particularly in real-world care settings. This study is a retrospective observational characterization of pediatric psoriasis patients managed in the Costa Rican Social Security System. Unlike interventional trials or biologic-specific registries, it analyzes existing clinical records to describe demographic distribution, clinical subtypes, severity (PASI/BSA/DLQI or pediatric indices), comorbidities, and treatment patterns in routine practice. No therapeutic interventions or standardized follow-up are introduced. By capturing real-world pediatric psoriasis presentation and management in Costa Rica, the study provides baseline national evidence distinct from drug-specific or prospective therapeutic studies.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- Up to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- The study population comprises children and adolescents (<18 years) with confirmed psoriasis managed in the Costa Rican Social Security System in Costa Rica. This retrospective hospital-based cohort includes patients across pediatric age groups and psoriasis subtypes receiving routine dermatologic care. Data derived from electronic health records and reflect real-world pediatric psoriasis severity, comorbidities, and treatment patterns in specialized tertiary care without protocol-mandated interventions.
Key inclusion criteria (4 listed)
- Patients younger than 18 years at the time of psoriasis diagnosis.
- Clinical diagnosis of psoriasis established by a specialist physician (dermatologist or trained pediatrician) or by a general practitioner within the Costa Rican Social Security System (CCSS).
- Patients evaluated in CCSS healthcare facilities between January 2018 and December 2025.
- Clinical records containing sufficient information on key epidemiologic and therapeutic variables relevant to the study (age, sex, date of diagnosis, clinical subtype, and treatment received).
Key exclusion criteria (3 listed)
- Patients aged 18 years or older at the time of psoriasis diagnosis.
- Clinical records incomplete or lacking sufficient information for analysis of the main study variables.
- Patients with uncertain or unconfirmed diagnosis of psoriasis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Treatment patterns used in pediatric psoriasis in real-world clinical practice (topical, phototherapy, systemic, biologic).
Time frame: January 2018- December 2025
Clinical and severity characteristics of pediatric psoriasis, including subtype and severity indices (e.g., PASI/BSA/DLQI or pediatric-adapted measures) documented in routine care.
Time frame: January 2018- December 2025
Comorbidity profile in pediatric psoriasis (e.g., metabolic, cardiovascular risk factors, psoriatic arthritis).
Time frame: January 2018- December 2025
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Apr 2026.
- Individual participant dataSharing planned: No. According to the protocol
Related trials for Pediatric Psoriasis
RecruitingPhase 3
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Crohns Disease, Colitis, Ulcerative
Active, not recruitingPhase 3
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
Psoriasis
Active, not recruitingPhase 3
A Long-term Extension Study of Ustekinumab in Pediatric Participants
Crohn Disease, Colitis, Ulcerative
Active, not recruitingObservational study
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
Psoriasis
RecruitingPhase 3
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pediatric Psoriasis, run by Caja Costarricense de Seguro Social at 1 site in Costa Rica.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Costa Rica. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Daniel E Barquero-Orias, Dermatologist (+506 83411026, debarque@ccss.sa.cr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Treatment patterns used in pediatric psoriasis in real-world clinical practice (topical, phototherapy, systemic, biologic). (time frame: January 2018- December 2025). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.